佛慈制药(002644) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥209,650,829.66, a decrease of 18.50% compared to the same period last year, which was ¥257,255,173.02[2] - Net profit attributable to shareholders for Q3 2024 was ¥2,977,662.84, an increase of 28.44% from ¥2,318,416.13 in the previous year[2] - The net profit after deducting non-recurring gains and losses for Q3 2024 was -¥2,588,474.97, a decrease of 63.63% compared to -¥1,581,954.58 last year[2] - Total operating revenue for Q3 2024 was CNY 708,531,496.45, a decrease of 19.7% compared to CNY 882,915,425.83 in the same period last year[14] - The net profit for Q3 2024 was CNY 40,448,681.79, a decrease of 33.3% compared to CNY 60,646,130.62 in Q3 2023[15] - The total comprehensive income attributable to the parent company was CNY 40,936,475.42, compared to CNY 60,684,637.33 in the same quarter last year[15] - The company’s total profit for the period was CNY 45,671,825.07, a decrease of 39.9% from CNY 76,020,298.36 in Q3 2023[15] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was -¥16,179,550.59, an improvement of 72.27% from -¥58,357,187.57 in the previous year[7] - The company's cash and cash equivalents decreased from 406,040,604.70 RMB to 351,622,449.61 RMB, a decline of approximately 13.4%[11] - Cash and cash equivalents at the end of the period totaled CNY 351,622,449.61, an increase from CNY 308,749,678.98 at the end of Q3 2023[17] - The total current assets decreased slightly from 1,238,869,322.84 RMB to 1,226,581,252.21 RMB, a decline of about 1.0%[11] - The company's total assets at the end of the reporting period were ¥2,528,102,214.36, a decrease of 2.24% from ¥2,471,584,976.31 at the beginning of the year[2] - Total assets decreased to CNY 2,471,584,976.31 from CNY 2,528,102,214.36, reflecting a decline of 2.2%[13] Shareholder Information - The total number of common shareholders at the end of the reporting period is 30,810[8] - The largest shareholder, Lanzhou Foci Pharmaceutical Industry Development Group Co., Ltd., holds 61.63% of the shares, totaling 314,713,676 shares[9] - The company has not disclosed any significant changes in the shareholding structure of the top ten shareholders due to margin trading activities[9] Operating Costs and Expenses - Total operating costs for Q3 2024 were CNY 651,587,799.98, down 21.0% from CNY 824,707,599.67 year-on-year[14] - The company incurred operating expenses of CNY 573,094,864.09, a decrease from CNY 830,641,632.62 in Q3 2023[16] - The company’s income tax expense for the quarter was CNY 5,223,143.28, down from CNY 15,374,167.74 in the same period last year[15] Investment and Financing - The company reported a significant decrease in investment income, with a loss of -¥6,521,859.04 compared to a profit of ¥1,192,877.25 in the previous year, a change of -646.73%[6] - The cash inflow from financing activities was CNY 10,050,000.00, down from CNY 16,160,000.00 in the previous year[17] Other Financial Metrics - The weighted average return on net assets for Q3 2024 was 0.17%, an increase of 0.04% from the previous year[2] - The company’s basic earnings per share for Q3 2024 was ¥0.0058, an increase of 28.89% from ¥0.0045 in the previous year[2] - The company reported a basic earnings per share of CNY 0.0765, down from CNY 0.1177 in the previous year[15] - Research and development expenses for Q3 2024 were CNY 21,768,633.09, slightly up from CNY 21,266,535.43 year-on-year[14] Changes in Liabilities and Equity - Total liabilities decreased to CNY 677,621,989.18, down 10.8% from CNY 759,672,279.87[13] - The total equity attributable to shareholders rose to CNY 1,769,241,841.60, up from CNY 1,745,370,807.77, reflecting an increase of 1.4%[13] - The company reported a significant reduction in accounts payable, which decreased to CNY 256,331,616.37 from CNY 282,938,778.50, a decline of 9.4%[12] Inventory and Receivables - Accounts receivable increased from 285,487,599.46 RMB to 343,973,094.80 RMB, representing a growth of about 20.5%[11] - Inventory rose from 369,720,187.96 RMB to 405,498,888.06 RMB, an increase of approximately 9.7%[11] - The company's accounts receivable financing decreased by 53.28% to ¥45,395,807.46, primarily due to increased use of endorsed notes for settlement with suppliers[4] Corporate Governance - The company completed the election of the eighth board of directors and supervisory board on August 14, 2024[10] - Deferred income tax assets increased to CNY 53,832,447.09 from CNY 53,648,272.25, indicating a slight growth[12] - Long-term equity investments decreased from 64,103,030.98 RMB to 57,546,825.06 RMB, a reduction of approximately 10.2%[11] - Fixed assets decreased from 1,056,198,751.95 RMB to 1,021,858,630.11 RMB, a decline of about 3.2%[11]